270 related articles for article (PubMed ID: 36508454)
1. Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
Chamchoy K; Sudsumrit S; Thita T; Krudsood S; Patrapuvich R; Boonyuen U
PLoS Negl Trop Dis; 2022 Dec; 16(12):e0010986. PubMed ID: 36508454
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Glucose 6-Phosphate Dehydrogenase Variants in Malaria-Endemic Areas of South Central Timor, Eastern Indonesia.
Sulistyaningrum N; Arlinda D; Hutagalung J; Sunarno S; Oktoberia IS; Handayani S; Ekowatiningsih R; Yusnita EA; Prasetyorini B; Rizki A; Tjitra E; Na-Bangchang K; Chaijaroenkul W
Am J Trop Med Hyg; 2020 Aug; 103(2):760-766. PubMed ID: 32602432
[TBL] [Abstract][Full Text] [Related]
3. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
Baird JK; Battle KE; Howes RE
Malar J; 2018 Jan; 17(1):42. PubMed ID: 29357870
[TBL] [Abstract][Full Text] [Related]
4. Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria.
Satyagraha AW; Sadhewa A; Panggalo LV; Subekti D; Elyazar I; Soebianto S; Mahpud N; Harahap AR; Baird JK
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009610. PubMed ID: 34270547
[TBL] [Abstract][Full Text] [Related]
5. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
[TBL] [Abstract][Full Text] [Related]
6. Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa.
Awandu SS; Raman J; Makhanthisa TI; Kruger P; Frean J; Bousema T; Niemand J; Birkholtz LM
Malar J; 2018 Mar; 17(1):120. PubMed ID: 29558929
[TBL] [Abstract][Full Text] [Related]
7. Genetic Variation of
Stewart AGA; Zimmerman PA; McCarthy JS
Front Pharmacol; 2021; 12():784909. PubMed ID: 34899347
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against
Dowd S; Chen N; Gatton ML; Edstein MD; Cheng Q
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0101423. PubMed ID: 37971260
[No Abstract] [Full Text] [Related]
9. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z
BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061
[TBL] [Abstract][Full Text] [Related]
10. Glucose-6-phosphate dehydrogenase deficiency prevalence and genetic variants in malaria endemic areas of Colombia.
Valencia SH; Ocampo ID; Arce-Plata MI; Recht J; Arévalo-Herrera M
Malar J; 2016 May; 15(1):291. PubMed ID: 27225440
[TBL] [Abstract][Full Text] [Related]
11. Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.
Sharma R; Sharma H; Jones S; Borghini-Fuhrer I; Domingo GJ; Gibson RA; Rolfe K; Tan L; Fiţa IG; Chen C; Bird P; Pingle A; Duparc S
Malar J; 2024 May; 23(1):145. PubMed ID: 38741094
[TBL] [Abstract][Full Text] [Related]
12. Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens.
Chu CS; Bancone G; Moore KA; Win HH; Thitipanawan N; Po C; Chowwiwat N; Raksapraidee R; Wilairisak P; Phyo AP; Keereecharoen L; Proux S; Charunwatthana P; Nosten F; White NJ
PLoS Med; 2017 Feb; 14(2):e1002224. PubMed ID: 28170391
[TBL] [Abstract][Full Text] [Related]
13. Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
Devine A; Battle KE; Meagher N; Howes RE; Dini S; Gething PW; Simpson JA; Price RN; Lubell Y
PLoS Med; 2021 Jun; 18(6):e1003614. PubMed ID: 34061843
[TBL] [Abstract][Full Text] [Related]
14. Single-Nucleotide Polymorphisms in Glucose-6-Phosphate Dehydrogenase and their Relevance for the Deployment of Primaquine as a Radical Cure for Malaria.
Nain M; Gill J; Mohan M; Sharma A
Am J Trop Med Hyg; 2023 Mar; 108(3):470-476. PubMed ID: 36746659
[TBL] [Abstract][Full Text] [Related]
15. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
Watson J; Taylor WRJ; Bancone G; Chu CS; Jittamala P; White NJ
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006440. PubMed ID: 29677199
[TBL] [Abstract][Full Text] [Related]
16. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rodrigo C; Rajapakse S; Fernando D
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD010458. PubMed ID: 32892362
[TBL] [Abstract][Full Text] [Related]
17.
Pett H; Bradley J; Okebe J; Dicko A; Tiono AB; Gonçalves BP; Stone W; Chen I; Lanke K; Neuvonen M; Mustaniemi AL; Eziefula AC; Gosling R; D'Alessandro U; Drakeley C; Niemi M; Bousema T
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383656
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.
Suarez-Kurtz G
Clin Pharmacol Ther; 2021 Sep; 110(3):595-598. PubMed ID: 34042179
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of G6PD Viangchan variant in malaria endemic areas in Lao PDR: an implication for malaria elimination by 2030.
Ong KIC; Iwagami M; Araki H; Khattignavong P; Soundala P; Keomalaphet S; Prasayasith P; Lorpachan L; Xangsayalath P; Pongvongsa T; Hongvanthong B; Brey PT; Kano S; Jimba M
Malar J; 2019 Mar; 18(1):75. PubMed ID: 30866940
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of G6PD deficiency and submicroscopic malaria parasites carriage in malaria hotspot area in Northwest, Tanzania.
Manjurano A; Lyimo E; Kishamawe C; Omolo J; Mosha J; Donald M; Kazyoba P; Kapiga S; Changalucha J
Malar J; 2023 Dec; 22(1):372. PubMed ID: 38062464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
